Repeated-Dose Pharmacodynamics of Pimobendan in Healthy Cats

被引:2
|
作者
Sugimoto, Keisuke [1 ]
Sugita, Kazutoshi [2 ]
Orito, Kensuke [2 ]
Fujii, Yoko [2 ]
机构
[1] Okayama Univ Sci, Fac Vet Med, Imabari City, Ehime 7948555, Japan
[2] Azabu Univ, Fac Vet Med, Sagamihara, Kanagawa 2525201, Japan
来源
ANIMALS | 2022年 / 12卷 / 08期
关键词
cardiac systolic function; feline; heart failure; hypertrophic cardiomyopathy; CONGESTIVE-HEART-FAILURE; MITRAL-VALVE DISEASE; UD-CG; 212; HYPERTROPHIC CARDIOMYOPATHY; DILATED CARDIOMYOPATHY; DOBERMAN-PINSCHERS; ORAL PIMOBENDAN; 115; BS; PHARMACOKINETICS; METABOLISM;
D O I
10.3390/ani12080981
中图分类号
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号
0905 ;
摘要
Simple Summary The dosing of pimobendan in cats is determined with reference to the effects of a single dose, although pimobendan is normally administered in repeated doses. In this study, the pharmacodynamics of repeated and multiple-dose pimobendan in healthy cats was investigated. Data were collected from five cats. Cardiac systolic function increased after repeated-dose pimobendan administration and correlated well with plasma concentrations of the drug. The results of this study suggest that a higher dose of pimobendan is effective. The aims of this study were to investigate the effects of repeated and multiple-dose pimobendan on cardiac systolic function and the correlations between changes in cardiac systolic function and plasma concentrations of pimobendan and O-desmethylpimobendan (ODMP). Five clinically healthy cats were subjected to four different medication protocols for 14 days, with a washout period of at least 1 month between each protocol. The protocols were pimobendan 0.5 mg/kg q12h (high dosage [HD] group); pimobendan 0.25 mg/kg q12h (standard dosage [SD] group); pimobendan 0.125 mg/kg q12h (low dosage group); and Biofermin R, one tablet q12h (placebo group). Echocardiography and measurement of plasma concentrations of pimobendan and ODMP were performed prior to medication administration (baseline) and 20, 40, 60, 120, 240, 360, and 480 min after administration, and the correlation between the changes in cardiac systolic function and plasma concentration of pimobendan, ODMP, or the sum of both were examined. The cardiac systolic function increased in the HD and SD groups, and there were significant correlations between the lateral peak systolic myocardial velocity (S ') changes and plasma pimobendan, plasma ODMP, and the sum of both. Repeated doses of pimobendan in healthy cats increased cardiac systolic function, and there were significant correlations between cardiac function and plasma concentrations of pimobendan and ODMP. The results of this study highlight the effectiveness of a higher dose of pimobendan.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Effect of pimobendan on the clinical outcome and survival of cats with non-taurine responsive dilated cardiomyopathy
    Hambrook, Lydia E.
    Bennett, Peter F.
    JOURNAL OF FELINE MEDICINE AND SURGERY, 2012, 14 (04) : 233 - 239
  • [22] Pharmacokinetics of Pimobendan and Its Metabolite O-Desmethyl-Pimobendan Following Rectal Administration to Healthy Dogs
    Her, Jiwoong
    Kuo, Kendon W.
    Winter, Randolph L.
    Cruz-Espindola, Crisanta
    Bacek, Lenore M.
    Boothe, Dawn M.
    FRONTIERS IN VETERINARY SCIENCE, 2020, 7
  • [23] Comparison of repeated-dose pharmacokinetics of prolonged-release and immediate-release torasemide formulations in healthy young volunteers
    Barbanoj, M. J.
    Ballester, M. R.
    Antonijoan, R. M.
    Gich, I.
    Pelagio, P.
    Gropper, S.
    Santos, B.
    Guglietta, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 (01) : 115 - 125
  • [24] Comparison of the effects of long-term pimobendan and benazepril administration in normal cats
    Miyagawa, Yuichi
    Machida, Noboru
    Toda, Noriko
    Tominaga, Yoshinori
    Takemura, Naoyuki
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2016, 78 (07) : 1099 - 1106
  • [25] Dose-Dependence and Repeated-Dose Studies for Receptor/Gene-Mediated Pharmacodynamics of Methylprednisolone on Glucocorticoid Receptor Down-Regulation and Tyrosine Aminotransferase Induction in Rat Liver
    Yu-Nien Sun
    Debra C. DuBois
    Richard R. Almon
    Nancy A. Pyszczynski
    William J. Jusko
    Journal of Pharmacokinetics and Biopharmaceutics, 1998, 26 : 619 - 648
  • [26] Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver
    Sun, YN
    DuBois, DC
    Almon, RR
    Pyszczynski, NA
    Jusko, WJ
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1998, 26 (06): : 619 - 648
  • [27] Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects
    Wang, Meng
    Zhou, Wenjia
    Zhang, Quanying
    Zong, Shunlin
    Lv, Chengzhe
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (05): : 602 - 609
  • [28] The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs
    Bell, E. T.
    Devi, J. L.
    Chiu, S.
    Zahra, P.
    Whittem, T.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2016, 39 (01) : 54 - 61
  • [29] Safety and Pharmacokinetic Profiles of Repeated-dose Micafungin in Children and Adolescents Treated for Invasive Candidiasis
    Benjamin, Daniel K., Jr.
    Deville, Jaime G.
    Azie, Nkechi
    Kovanda, Laura
    Roy, Mike
    Wu, Chunzhang
    Arrieta, Antonio
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (11) : E419 - E425
  • [30] In vitro blood-brain barrier model adapted to repeated-dose toxicological screening
    Fabulas-da Costa, A.
    Aijjou, R.
    Hachani, J.
    Landry, C.
    Cecchelli, R.
    Culot, M.
    TOXICOLOGY IN VITRO, 2013, 27 (06) : 1944 - 1953